Modified GRF 1-29 (AKA Mod GRF 1-29, CJC-1295)

Half Life: 30 minutes

Overview and History of Modified GRF 1-29 (CJC-1295 without DAC)

The Modified GRF 1-29 is also known as the Mod GRF 1-29, but is more commonly known as the CJC-1295 without DAC.

The correct terminology, however, is its original name and classification: Pre-Substituted GRF (1-29).

We need to clear up the confusion about the name and nomenclature of this particular substance first, as it is clear that most of the performance enhancing drug community and individuals looking to use this substance will be very confused when reading and researching it, especially when deciding to purchase it later on (it is labeled by all names by some vendors and only one name by others).

The name Mod GRF 1-29 was originally coined by a researcher named DatBtrue in a publicly available article on the internet about this substance.

As his article gained popularity, the new name was easily and widely adopted by readers, and it has been in widespread use ever since.

However, the most common name for the substance is probably CJC-1295, which is DAC-free.

The key to understanding the difference between these names is the history and structure of the substance.

Mod GRF 1-29 belongs to a category of peptides known as human growth hormone (HGH) secretagogues.

It is a modified derivative of an existing derivative of growth hormone releasing hormone (GHRH), a peptide hormone produced endogenously in the human body.

Therefore, it may be more appropriate to call them second-generation derivatives of GHRH.

GHRH is modified to produce a substance known as growth hormone releasing factor (GRF) 1-29.

GRF 1-29 is then further modified to create Mod GRF 1-29.

The nomenclature for the evolution of the derivatives should be self-explanatory.

GRF 1-29 is also known by the trade name sermorelin (a derivative of Mod GRF 1-29).

However, the most widely recognized name for this peptide is CJC-1295 without DAC, which is so called because there is actually a third derivative known as CJC-1295 with DAC.

The acronym DAC stands for Drug Affinity Complex, which is a modification added to a peptide to extend its half-life and active life in the body.

CJC-1295 without DAC is simply Mod GRF 1-29.

For the reader's clarification and understanding, here's what we've discussed so far

GRF 1-29 is a modification of growth hormone releasing hormone (GHRH).

Mod GRF 1-29 is a variant of GRF 1-29.

CJC-1295 with DAC is a variant of Mod GRF 1-29.

Now that the confusing naming scheme is clear, here is a general description of Mod GRF 1-29:

Mod GRF 1-29 is a peptide hormone (also known as a protein hormone) developed in Canada and first mentioned in the medical literature in 2005[i].

It is a protein composed of 29 amino acids and is a GHRH analog, as previously described. As a GHRH analog, Mod GRF 1-29 (CJC-1295 without DAC) acts on receptors in the pituitary gland to stimulate the release of human growth hormone.

In order to understand its function and what it is, it is necessary to understand the concept of the protein/peptide structure of these hormones (which in turn will help the reader further understand the difference in nomenclature discussed above)

Chemical Properties of Modified GRF 1-29 (CJC-1295 without DAC)

Proteins/peptides are chains of amino acids linked in a specific, unique order.

Depending on how many amino acids they are made up of, proteins appear as one of the following types of structures: primary protein structures, which are simply long chains of amino acids; secondary protein structures, which are folded proteins like wrinkled sheets; tertiary protein structures, which are folded proteins as complex as a ball of tangled threads; and finally quaternary protein structures, which are multiple tertiary proteins linked together.

The reason this is important for protein hormones like human growth hormone (HGH), insulin, luteinizing hormone (LH), and Mod GRF 1-29 (CJC-1295 without DAC) is that different parts of the protein structure bind to and activate different receptors to do different things in the body.

Depending on the shape of the peptide hormone and its subsections, it may have a stronger or weaker binding affinity.

Growth hormone releasing hormone (GHRH), which is endogenously secreted by the arcuate nucleus of the human hypothalamus, is composed of 44 amino acids.

However, it has been found that only the first 29 amino acids of the protein are as effective at binding to receptors in the pituitary gland as the full 44-amino acid structure[ii] [iii].

The first 29 amino acids of the protein structure were then isolated and called GRF 1-29, but the problem with this GHRH derivative was that it was rapidly metabolized by enzymes and eliminated from the body.

Studies have shown that GRF 1-29 has a half-life of less than 10 minutes to just 5 minutes[iv].

This is clearly insufficient time for maximum and sustained release of HGH from the pituitary gland, as studies have demonstrated that at least 30 minutes is required for maximum and sustained release of HGH from the pituitary gland, and in light of the fact that much higher HGH levels (over 50-fold) have been observed 15-30 minutes after subcutaneous administration of GHRH analogs[v].

The solution to this was therefore to modify GRF 1-29 by replacing various amino acids in the structure with others that would provide greater resistance to degradation and cleavage by enzymes.

Many modified analogs were developed, of which Mod GRF 1-29 (CJC-1295 without DAC) was ultimately selected for use as it showed the most promising effects.

Mod GRF 1-29 is a modification of GRF 1-29, specifically at amino acids 2, 8, 15, and 27.

This resulted in an extended half-life of at least 30 minutes [vi] [vii].

Characterization of Modified GRF 1-29 (CJC-1295 without DAC)

Mod GRF 1-29 acts on receptors located in the anterior pituitary gland, signaling the pituitary gland to increase human growth hormone production and triggering the pulsatile release of large amounts of human growth hormone.

The effects of Mod GRF 1-29 are very similar to what you would expect from long-term administration of synthetic human growth hormone (see our human growth hormone profile here), but the amount of time the released human growth hormone circulates is much less than synthetic human growth hormone.

Therefore, to ensure that human growth hormone levels remain consistently high, it is recommended to administer multiple doses of Mod GRF 1-29 throughout the day.

Mod GRF 1-29 (CJC-1295 without DAC) is typically combined with a ghrelin mimetic (growth hormone releasing hexapeptide) such as GHRP-6, GHRP-2, hexarelin, or ipamorelin to initiate and amplify more HGH pulses from the pituitary gland compared to Mod GRF 1-29 used alone.

The effects of a GHRH analog (such as Mod GRF 1-29) and a ghrelin mimetic (such as GHRP-6 or ipamorelin) work synergistically to amplify the release of HGH from the pituitary gland.

CJC-1295 Side Effects

The side effects associated with Mod GRF 1-29 can all be attributed to the side effects of human growth hormone, and the actual specific end result of Mod GRF 1-29 (CJC-1295 without DAC) can be seen as achieving a massive increase in naturally occurring endogenous human growth hormone.

Therefore, it is important to understand that the side effects of Mod GRF 1-29 are primarily and almost exclusively caused by the increase in HGH that is induced in the human body.

Neither HGH nor Mod GRF 1-29 is a sex hormone, so you should not expect the types of side effects associated with anabolic steroids (such as androgenic side effects and infertility).

Therefore, Mod GRF 1-29 is just as suitable for women as it is for men.

While some side effects have been reported, including nausea, dizziness, and lightheadedness, the side effects of Mod GRF 1-29 alone are considered to be minimal to the point of being almost non-existent.

In fact, as many users have reported, especially when stacked with GHRP, Mod GRF 1-29 almost always causes tingling in the extremities and a “pins and needles” sensation, as well as a common “light headed” feeling.

This is strong evidence that the hormone is indeed stimulating the pituitary gland.

In addition to the Mod GRF 1-29 side effects caused by the peptide itself, there are all the side effects associated with human growth hormone as mentioned earlier.

The most common side effects include flu-like symptoms, joint pain, carpal tunnel syndrome, headaches, abdominal bloating, and water retention.

Less common side effects include dizziness, tingling or numbness of the skin, decreased tactile sensitivity, nausea, bone pain, and gynecomastia.

HGH is not a sex hormone, but it acts as an important mediating hormone that works in conjunction with estrogen in the development of gynecomastia [1].

Therefore, this should be kept in mind when using Mod GRF 1-29 (or any HGH related compound) in conjunction with anabolic steroids.

For a more detailed description of the side effects of using human growth hormone, please refer to the Human Growth Hormone Side Effects section of our Human Growth Hormone profile.

CJC-1295 Cycles and Uses

Mod GRF 1-29 is a peptide hormone that signals the release of endogenous manufactured human growth hormone from the pituitary gland, as opposed to the administration of exogenous synthetic human growth hormone via injection as previously described.

Therefore, for all intents and purposes, Mod GRF 1-29 is considered a type of human growth hormone product/compound.

It should be clear that it is not human growth hormone itself, but rather triggers the pulsatile release of endogenously manufactured human growth hormone.

Therefore, a Mod GRF 1-29 cycle should be treated in essentially the same way as an exogenous HGH cycle.

This type of cycle is very different from an anabolic steroid cycle and cannot be considered or treated as such.

Due to the unique nature of the compound, there is no such thing as a “beginner Mod GRF 1-29 cycle” or an “advanced Mod GRF 1-29 cycle”.

Mod GRF 1-29 (CJC-1295 without DAC) has a very wide range of use, and the dosing cycle is the only factor that determines what results will be seen based on the individual user's goals.

Mod GRF 1-29 cycles can basically be broken down into three main categories

- Mod GRF 1-29 cycles for muscle growth and fat loss

- Mod GRF 1-29 cycles for body fat loss

- Mod GRF 1-29 cycles for anti-aging and general well-being

The nature of all human growth hormone cycles (and therefore all Mod GRF 1-29 cycles) is the long-term nature of the cycle.

Human growth hormone and Mod GRF 1-29 cycles are long-term cycles, at least in the 4-6 month range.

This is very different from anabolic steroid cycles, which are often weeks rather than months in duration.

This is because the nature of human growth hormone and its effects on the body are cumulative and steady, with results typically not being observed until several weeks after use, and the longer the cycle, the more pronounced the results.

A Mod GRF 1-29 cycle to achieve both muscle growth and fat loss is to administer 100 mcg of Mod GRF 1-29 (CJC-1295 without DAC) at least three times a day for 4-6 months.

To achieve both significant muscle growth and fat loss, it is ideal to administer Mod GRF 1-29 four to five times per day for four to six months, with at least three hours between each dose.

The increased amount of HGH pulses from the pituitary gland should ensure a sustained rise in naturally occurring endogenous HGH.

A Mod GRF 1-29 cycle for fat loss only should involve the administration of 100 mcg of Mod GRF 1-29 (CJC-1295 without DAC) two to three times per day (but ideally three times per day) for 4 to 6 months.

This application should provide enough pulses of HGH to experience lipolytic effects.

Depending on your nutrition and training, you may also experience some muscle gains.

Mod GRF 1-29 cycles for anti-aging and overall well-being should be administered at 100mcg of Mod GRF 1-29 (CJC-1295 without DAC) once or twice daily for 4-6 months.

While the HGH pulse from the pituitary gland with these Mod GRF 1-29 cycles is minimal, these protocols should ensure that enough HGH is released to provide general healing, recovery, anti-aging, and well-being enhancement.

It is very important to note that the cycle length and dosage provided does not determine whether a particular Mod GRF 1-29 cycle will result in fat loss and/or muscle growth, nutrition and training will!

The compound itself will only help you move faster in the direction you want to go, but it's your nutrition and training that will determine whether or not you get there.

To increase the effectiveness of a Mod GRF 1-29 (CJC-1295 without DAC) cycle, it is ideal to stack it with some sort of GHRP for proper synergy for a larger HGH pulse, as previously mentioned in this profile.

The Mod GRF 1-29 cycle can easily be run with synthetic HGH, anabolic steroids, and other peptides such as IGF-1.

Mod GRF 1-29 cycles should be run long term, in the range of at least 4-6 months, but an occasional anabolic steroid cycle can be interspersed during this time to take full advantage of the human growth hormone increase triggered by Mod GRF 1-29 (CJC-1295 without DAC) and the synergistic effects of anabolic steroids.

The combination of synthetic exogenous HGH and Mod GRF 1-29 is very common among those who can afford it, and typically consists of administering a 4iu dose of synthetic exogenous HGH right in the morning, followed by Mod GRF 1-29 during the day (with another optional HGH dose 30 minutes later), and finally Mod GRF 1-29 again just before bedtime.

This protocol of Mod GRF 1-29 cycles ensures maximum effectiveness of HGH and is much more cost-effective than administering higher doses of synthetic HGH alone.

CJC-1295 Administration and Dosage

Mod GRF 1-29 and most other growth hormone releasing peptides are fairly new to the market, and at this point there is limited clinical data and general information regarding Mod GRF 1-29 dosage.

While it is true that solid protocols have been developed, it is important to note that Mod GRF 1-29 (CJC-1295 without DAC) has not yet been medically approved or utilized, and clinical trials for Mod GRF 1-29, as well as many other peptide hormones, are still under investigation.

Nevertheless, the limitations of clinical data and general information about CJC-1295 without DAC have not prevented athletes, bodybuilders, and others in the performance-enhancing drug-using community from benefiting from its use.

Therefore, there is currently sufficient data to provide information on appropriate and effective Mod GRF 1-29 doses.

Naturally, endogenously produced GHRH is secreted by the hypothalamus and travels directly to the anterior pituitary gland, where it binds to receptors there and stimulates the release of HGH.

GHRH and its analogs (e.g. Mod GRF 1-29) already tend to have a very short half-life due to the high affinity of the peptide's amino acid bonds to be cleaved by enzymes in the body.

Naturally secreted GHRH doesn't travel very far between the hypothalamus and pituitary gland, so very little of it is broken down by enzymes in transit.

However, Mod GRF 1-29 and related GHRH analogs must travel a long distance through the circulation to the pituitary gland after injection, and degradation of the peptide already occurs within about 3 minutes.

Therefore, the dose of Mod GRF 1-29 must be high compared to endogenous GHRH in order for the receptors in the anterior pituitary to reach saturation.

The saturation dose is defined as the dose that completely saturates the target receptors in the body (in this case, the receptors located in the anterior pituitary).

This means that a 100 mcg saturation dose will fully saturate the receptor, 200 mcg will only provide 50% of the additional effect, 300 mcg will only provide 25% of the additional effect, and so on.

Mod GRF 1-29 doses are measured in mcg (micrograms), while other performance enhancing drugs (such as anabolic steroids) are typically measured in mg (milligrams), and readers should be aware of this. Synthetic human growth hormone (HGH) is measured in iu (international units). This difference should be taken into account when distinguishing between different dosage measurements.

Medical Modified GRF 1-29 (CJC-1295 without DAC) Dosage

As Mod GRF 1-29 (CJC-1295 without DAC) is not currently approved for medical use and is still in clinical trials, there is no prescribed medical dosage available at this time.

Mod GRF 1-29 (CJC-1295 without DAC) Dosage for Performance and Physique Enhancement

For performance and physique enhancement purposes, peptides like Mod GRF 1-29 in particular, cannot be categorized into three tiers of users (beginner, intermediate, advanced) due to the unique nature of the substance and hormone type.

As a result, there is a single protocol for Mod GRF 1-29 dosage that is generally determined and established because the increase in HGH from the pituitary gland is usually large enough to benefit everyone.

Studies have shown that an effective saturating dose of Mod GRF 1-29 is 100 mcg/kg body weight[1] [2] [3] [4].

To take 100 mcg of Mod GRF 1-29, a person would need to weigh 100 kg (220 pounds).

Therefore, for ease of administration and to avoid confusion, we use 100mcg as the standard generic Mod GRF 1-29 dose to ensure that the receptors in the anterior pituitary reach saturation at any given time for nearly all users.

Due to the short half-life of 30 minutes and the resulting pulsatile nature of HGH release, 100mcg should be administered three times a day, evenly spaced, to reach substantial HGH levels throughout the day (more on this shortly).

Modified GRF 1-29 (CJC-1295 without DAC) Dosage for Women

Mod GRF 1-29 is not a gender-specific hormone, meaning it does not have androgenic effects that can cause problems.

Therefore, the Mod GRF 1-29 dosage for women is exactly the same as the dosage for men and everyone else.

Proper Dosage and Timing of Modified GRF 1-29 (CJC-1295 without DAC)

Mod GRF 1-29 is typically manufactured as a lyophilized (freeze-dried) powder at 2 mg per vial.

This powder in the vial should be reconstituted with bacteriostatic water prior to injection and refrigerated immediately after reconstitution and after use due to the nature of the peptide.

If left unrefrigerated at room temperature for extended periods of time, the reconstituted peptide will rapidly degrade and become ineffective.

When reconstituting, 2 ml of bacteriostatic water is typically gently mixed into the powder to obtain a Mod GRF 1-29 dose of 100 mcg (or 10iu in an insulin syringe) per 0.1 ml, which is typically the amount of 2 mg of powder.

Mod GRF 1-29 (CJC-1295 without DAC) can be administered subcutaneously (SQ) or intramuscularly (IM).

There is not much difference between the two, and intramuscular administration seems to result in a slightly faster release from the injection site.

However, most people prefer subcutaneous administration for a variety of reasons.

There are a few important points to consider and understand regarding Mod GRF 1-29 doses (or any type of GHRH doses).

The first point is that GHRH should be administered 30 minutes before a meal containing fat and carbohydrates and at least 2 hours after a meal containing fat and carbohydrates.

This is because both fat and carbohydrates have the effect of slowing the release of HGH from the pituitary gland, so consuming these two macronutrients too soon before or after administration can prevent the full release of HGH from the pituitary gland.

Once HGH levels peak in the pulse 30 minutes after administration, it is safe to consume a meal containing carbohydrates and fats.

Since GHRH analogs such as Mod GRF 1-29 (CJC-1295 without DAC) stimulate HGH release in a pulsatile manner, it is usually necessary to administer multiple doses of Mod GRF 1-29 throughout the day, with an average of three evenly spaced doses per day.

The most common protocols are

100 mcg immediately after waking up.

100 mcg immediately after finishing a workout

100 mcg just before going to bed

A GRF 1-29 dose of 100 mcg three times a day is believed to release the HGH needed for bodybuilding and athletic performance.

Some choose to take it twice a day (100 mcg in the morning and 100 mcg before bed), which is said to provide the desired HGH release for anti-aging and general health benefits.

Some people choose to take Mod GRF 1-29 (CJC-1295 without DAC) three or more times a day, which can obviously produce much higher levels of HGH.

However, for optimal release, it is important to leave at least a 3-hour gap between each dose of GHRH to allow adequate HGH levels to once again be restored within the pituitary gland.

We mentioned earlier that GHRH analogs such as Mod GRF 1-29 should generally be used in conjunction with a GHRP (also known as a ghrelin mimetic) such as GHRP-6 or Ipamorelin.

This is because GHRH and GHRP peptides work synergistically in the way they stimulate the anterior pituitary gland to release HGH.

GHRH alone is only effective when somatostatin (a hormone that inhibits the release of HGH from the pituitary gland) is low.

All GHRPs act to suppress somatostatin, and this will be one of the many ways that GHRPs will enhance the effects of Mod GRF 1-29 (or any GHRH).

To summarize the synergy of the two in general terms, a GHRH analog (such as Mod GRF 1-29) acts to initiate and deliver a pulse of HGH from the pituitary gland, and a GHRP (such as GHRP-6) acts to amplify this pulse.

Finally, research [5] has shown that a single dose of 100 mcg of GHRH alone results in the release of 25 ng/ml of HGH from the pituitary gland.

In the same study, when combined with a GHRP (GHRP-6), the resulting amount of HGH released was found to be 130 ng/ml.

Expectations and Results from Modified GRF 1-29 (CJC-1295 without DAC) Administration

The results and expected effects of human growth hormone such as Mod GRF 1-29 should be all the same as those provided by other forms of human growth hormone.

This includes fat loss, muscle mass gains, strength gains, joint and connective tissue healing and repair, and numerous other benefits and changes.

Importantly, the effects of any HGH application, whether it's endogenous release via GHRH or synthetic HGH administration, all occur steadily over a long period of time.

While you shouldn't expect to see dramatic results in a matter of weeks, months of consistent use with proper nutrition and training can result in dramatic performance and physique changes.

For more information on the specific results and expectations of HGH, see our Human Growth Hormone profile.

CJC-1295 buy online and legality:

Since Mod GRF 1-29 is a fairly new peptide on the market, those looking to buy Mod GRF 1-29 will be happy to know that it is generally legal to use as a research chemical in almost all countries.

It is very simple to manufacture compared to other peptides, and since nothing is legally regulated, it is freely sold on the open market without fear of legal penalties.

Those looking to purchase Mod GRF 1-29 will find almost exclusively research-grade products.

This means that research-grade Mod GRF 1-29 is typically sold as a lyophilized (freeze-dried) powder with 2 mg per vial.

These vials must be reconstituted with bacteriostatic water before injection.

Mod GRF 1-29 is currently available for legal use as a research chemical in most countries around the world, including the United States, Canada, and the United Kingdom.

It is still in the clinical research phase in medical institutions, and most major countries do not yet have regulations or timelines for this peptide.

Also, while there are no laws prohibiting the personal use of Mod GRF 1-29, all readers should understand that the currently available Mod GRF 1-29 is for research purposes only and is not intended for human use.

CJC-1295 References

[i] Human growth hormone releasing factor (hGRF)1-29-albumin bioconjugate activates GRF receptors in the anterior pituitary of rats: Identification of CJC-1295 as a long-acting GRF analog. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Endocrinology. 2005 Jul;146(7):3052-8. Epub 2005 Apr 7.

[II] In vivo biological efficacy of rat and human growth hormone releasing factor and human growth hormone releasing factor fragments. Wehrenberg WB, Ling N. (1983). Biochemical and biophysical research communications 115 (2): 525–530. doi:10.1016/S0006-291X(83)80176-4

[iii] Response to growth hormone-releasing hormone analogs in normal subjects and in growth hormone-deficient children and adolescents. Grossman A, Savage M, Litras N, et al (1984). Clin Endocrinol (Oxf) 21 (3): 321-330.

[iv] Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. Frohman LA (1986). J Clin Invest 78 (4): 906–913. doi:10.1172/JCI112679.

[V] A potent trypsin-resistant hGH-RH analog. Izdebski J, Witkowska E, Kunce D, Orłowska A, Baranowska B, Wolińska-Witort E. 2004 Aug;10(8):524-9.

[vi] New potent hGH-RH analogs with increased resistance to enzymatic degradation. Izdebski J (2002). Endocrinology. 8 (7): 285-287.

[vii] Human growth hormone releasing factor (hGRF) 1-29-albumin bioconjugate activates GRF receptors in the anterior pituitary of rats: Identification of CJC-1295 as a long-acting GRF analog. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP (2005). Endocrinology 146 (7): 3052-8.

] Effects of GRCWTH hormone-releasing factor in men. Marie C. Gelato, Ora Peskovitz, Fernando Casola, D. Lynn Fernando, George R. Merriam. Journal of Clinical Endocrinology and Metabolism September 1 1983 Volume 57 Issue 3 674-676.

[2] α2-adrenergic agonists enhance growth hormone (GH) response to growth hormone releasing hormone via inhibition of hypothalamic somatostatin release in normal men*. Jesus Devesa, Victor Arce†, Noemi Royce, Jesus A. F. Tresguerres, Luis Lima. Journal of Clinical Endocrinology and Metabolism December 1, 1990, Volume 71, Issue 6, Pages 1581-1588

[3] Glucocorticoids may inhibit growth hormone release by enhancing beta-adrenergic reactivity in hypothalamic somatostatin neurons. L Lima, V Arce, M J Diaz, J A Tresguerres, J Devesa. Journal of Clinical Endocrinology and Metabolism Feb 1 1993 Vol 76 No 2 pp 439-444.

[4] The human growth hormone releasing factor (hGRF)1-29-albumin bioconjugate activates GRF receptors in the anterior pituitary of rats: Identification of CJC-1295 as a long-acting GRF analog. Lucie Jette, Roger Leger, Karen Thibodeau, Corinne Benke, Martin Robitaille, Isabelle Pellerin, Veronique Paradis, Peter Van Wyk, Khanh Pham, Dominique P. Bridon. Endocrinology July 1, 2005, Volume 146, Number 7 3052-3058.

[5] Suppression of growth hormone release after co-administration of GHRH and GHRP-6 in patients with Cushing's syndrome. Real-Cero A, Fumar A, García-García E, Diguez C, Casanueva FF. Clin Endocrinol (Oxf). 1994 Nov;41(5):649-54.